Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2003. The report details a specific corporate action regarding share re-purchases authorized by shareholders at the Annual General Meeting on May 20, 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 870,000 ordinary shares
- Purchase Date: February 19, 2003
- Price per Share: 1149.46p
- Transaction Purpose: Cancellation of shares
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. The primary change reported is the reduction of the company's share capital through the cancellation of 870,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is a routine disclosure of a share buyback execution.
Investor Verification Points
- Verify the total number of shares remaining outstanding following the cancellation of 870,000 shares.
- Confirm the total remaining authority for share re-purchases under the mandate granted on May 20, 2002.
- Review the company's full annual or interim financial reports for comprehensive revenue and profit data, as this filing is limited to the share transaction.